New News information at Drug Development Technology New and updated information from News listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New News information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Celyad commences Phase I trial of CYAD-01 to treat colorectal cancer http://www.drugdevelopment-technology.com/news/newscelyad-starts-phase-i-trial-of-cyad-01-to-treat-colorectal-cancer-5877637 http://www.drugdevelopment-technology.com/news/newscelyad-starts-phase-i-trial-of-cyad-01-to-treat-colorectal-cancer-5877637 Belgian biopharmaceutical firm Celyad has commenced a Phase I clinical trial (SHRINK) of its product candidate CYAD-01 (CAR-T NKG2D) for the treatment of patients with metastatic colorectal cancer. Thu, 20 Jul 2017 23:00:00 GMT CTD Holdings begins dosing in Phase I/II trial of Trappsol Cyclo to treat NPC http://www.drugdevelopment-technology.com/news/newsctd-holdings-begins-dosing-in-phase-iii-trial-of-trappsol-cyclo-to-treat-npc-5877615 http://www.drugdevelopment-technology.com/news/newsctd-holdings-begins-dosing-in-phase-iii-trial-of-trappsol-cyclo-to-treat-npc-5877615 CTD Holdings has commenced patient dosing in a Phase I/II clinical trial of its intravenous drug candidate Trappsol Cyclo for the treatment of patients in Europe with Niemann-Pick disease type C (NPC). Thu, 20 Jul 2017 23:00:00 GMT Deals this week: AntriaBio, Race Oncology, Invenra http://www.drugdevelopment-technology.com/news/newsdeals-this-week-antriabio-race-oncology-invenra-5876046 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-antriabio-race-oncology-invenra-5876046 AntriaBio has announced the private placement of 4.5 million shares of its common stock, priced at $1 a share, to raise $4.5m in gross proceeds. Thu, 20 Jul 2017 23:00:00 GMT Nektar reports positive top-line results from HAP study of NKTR-181 for chronic pain http://www.drugdevelopment-technology.com/news/newsnektar-reports-positive-top-line-results-from-hap-study-of-nktr-181-for-chronic-pain-5876364 http://www.drugdevelopment-technology.com/news/newsnektar-reports-positive-top-line-results-from-hap-study-of-nktr-181-for-chronic-pain-5876364 US-based biopharmaceutical firm Nektar Therapeutics has reported positive top-line results from an oral human abuse potential (HAP) study of its opioid analgesic, NKTR-181, for chronic pain. Wed, 19 Jul 2017 23:00:00 GMT Tiziana enrols first patient in Phase IIa trial of milciclib to treat HCC http://www.drugdevelopment-technology.com/news/newstiziana-enrols-first-patient-in-phase-iia-trial-of-milciclib-to-treat-hcc-5876670 http://www.drugdevelopment-technology.com/news/newstiziana-enrols-first-patient-in-phase-iia-trial-of-milciclib-to-treat-hcc-5876670 UK-based biotechnology firm Tiziana Life Sciences has started patient enrolment in a Phase IIa clinical trial of milciclib for the treatment of hepatocellular carcinoma (HCC) patients. Wed, 19 Jul 2017 23:00:00 GMT TopiVert and Onynx initiate clinical trials of NSKI drugs http://www.drugdevelopment-technology.com/news/newstopivert-and-onynx-initiate-clinical-trials-of-nski-drugs-5876375 http://www.drugdevelopment-technology.com/news/newstopivert-and-onynx-initiate-clinical-trials-of-nski-drugs-5876375 UK-based biotechnology firm TopiVert has initiated clinical trials of two of its narrow spectrum kinase inhibitor (NSKI) drug candidates, TOP1288 and TOP1630, with support from contract research organisation (CRO) Onyx Scientific. Wed, 19 Jul 2017 23:00:00 GMT Sunesis starts dosing in Phase Ib/II trial of SNS-062 for B-cell malignancies http://www.drugdevelopment-technology.com/news/newssunesis-starts-dosing-in-phase-ibii-trial-of-sns-062-for-b-cell-malignancies-5875273 http://www.drugdevelopment-technology.com/news/newssunesis-starts-dosing-in-phase-ibii-trial-of-sns-062-for-b-cell-malignancies-5875273 Sunesis Pharmaceuticals has started dosing patients in a Phase Ib/II clinical trial of SNS-062 to treat patients with B-cell malignancies such as chronic lymphocytic leukaemia (CLL), small lymphocytic leukaemia, Waldenstrom’s macroglobulinemia and ma… Tue, 18 Jul 2017 23:00:00 GMT CPP initiates NCI-funded Phase II trial of CPP-1X for gastric cancer http://www.drugdevelopment-technology.com/news/newscpp-initiates-nci-funded-phase-ii-trial-of-cpp-1x-for-gastric-cancer-5874720 http://www.drugdevelopment-technology.com/news/newscpp-initiates-nci-funded-phase-ii-trial-of-cpp-1x-for-gastric-cancer-5874720 US-based Cancer Prevention Pharmaceuticals (CPP) has initiated a Phase II clinical trial of CPP-1X for the treatment of precancerous gastric lesion patients who are at high gastric cancer risk. Tue, 18 Jul 2017 23:00:00 GMT Can-Fite commences Phase II trial of namodenoson for NAFLD/NASH http://www.drugdevelopment-technology.com/news/newscan-fite-starts-phase-ii-trial-of-namodenoson-for-nafldnash-5874733 http://www.drugdevelopment-technology.com/news/newscan-fite-starts-phase-ii-trial-of-namodenoson-for-nafldnash-5874733 Israeli biotechnology firm Can-Fite BioPharma is set to commence patient enrolment for a Phase II clinical trial of namodenoson to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), following the successful conc… Tue, 18 Jul 2017 23:00:00 GMT Apexigen starts dosing in Phase Ib/II combination trial for solid tumours http://www.drugdevelopment-technology.com/news/newsapexigen-starts-dosing-in-phase-ibii-combination-trial-for-solid-tumours-5873574 http://www.drugdevelopment-technology.com/news/newsapexigen-starts-dosing-in-phase-ibii-combination-trial-for-solid-tumours-5873574 Apexigen has started dosing patients in a Phase Ib/II clinical trial of APX005M in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) to treat patients with advanced solid tumours. Mon, 17 Jul 2017 23:00:00 GMT New NYU Langone trial shows role of drug + CI-PCM care in Alzheimer's http://www.drugdevelopment-technology.com/news/newsnew-nyu-langone-trial-shows-role-of-drug-ci-pcm-care-in-alzheimers-5873240 http://www.drugdevelopment-technology.com/news/newsnew-nyu-langone-trial-shows-role-of-drug-ci-pcm-care-in-alzheimers-5873240 A new trial conducted by NYU Langone Medical Centre in the US has demonstrated a favourable outcome with the combination of a common Alzheimer's disease drug and a specific care management programme. Mon, 17 Jul 2017 23:00:00 GMT Wave Life Sciences begins Phase Ib/IIa trials of two Huntington’s disease drugs http://www.drugdevelopment-technology.com/news/newswave-life-sciences-begins-phase-ibiia-trials-of-two-huntingtons-disease-drugs-5873252 http://www.drugdevelopment-technology.com/news/newswave-life-sciences-begins-phase-ibiia-trials-of-two-huntingtons-disease-drugs-5873252 Wave Life Sciences has begun new Phase Ib/IIa clinical trials (PRECISION-HD1 and PRECISION-HD2) of WVE-120101 and WVE-120102 to treat patients suffering with Huntington’s disease (HD). Mon, 17 Jul 2017 23:00:00 GMT Foundation Medicine to support enrolment for Kura Oncology’s SCCHN trials http://www.drugdevelopment-technology.com/news/newsfoundation-medicine-to-support-enrolment-for-kura-oncologys-scchn-trials-5872440 http://www.drugdevelopment-technology.com/news/newsfoundation-medicine-to-support-enrolment-for-kura-oncologys-scchn-trials-5872440 US-based biopharmaceutical firm Kura Oncology has signed a collaboration agreement with Foundation Medicine to support patient enrolment into its clinical programme of tipifarnib to treat relapsed and / or refractory HRAS mutant squamous cell carcino… Sun, 16 Jul 2017 23:00:00 GMT Innovation reports positive top-line results from Phase II trial of IBD drug http://www.drugdevelopment-technology.com/news/newsinnovation-reports-positive-top-line-results-from-phase-ii-trial-of-ibd-drug-5871950 http://www.drugdevelopment-technology.com/news/newsinnovation-reports-positive-top-line-results-from-phase-ii-trial-of-ibd-drug-5871950 Innovation Pharmaceuticals has reported positive top-line results from a Phase II clinical trial of brilacidin in patients with inflammatory bowel disease (IBD) types known as ulcerative proctitis and ulcerative proctosigmoiditis (UP/UPS). Sun, 16 Jul 2017 23:00:00 GMT Halozyme initiates Phase Ib/II oncology combination trial http://www.drugdevelopment-technology.com/news/newshalozyme-initiates-phase-ibii-oncology-combination-trial-5871936 http://www.drugdevelopment-technology.com/news/newshalozyme-initiates-phase-ibii-oncology-combination-trial-5871936 US-based biotechnology firm Halozyme Therapeutics has initiated a Phase Ib/II clinical trial of PEGPH20 and atezolizumab (Tecentriq) combination to treat metastatic pancreatic ductal adenocarcinoma. Sun, 16 Jul 2017 23:00:00 GMT Deals this week: MyoKardia, Kala Pharmaceuticals, Mesoblast http://www.drugdevelopment-technology.com/news/newsdeals-this-week-myokardia-kala-pharmaceuticals-mesoblast-5869308 http://www.drugdevelopment-technology.com/news/newsdeals-this-week-myokardia-kala-pharmaceuticals-mesoblast-5869308 MyoKardia has announced plans to issue more than nine million shares of its common stock priced at $13.3 a share, to raise $122.15m in gross proceeds. Thu, 13 Jul 2017 23:00:00 GMT Amgen’s multiple myeloma drug shows positive outcome in Phase III trial http://www.drugdevelopment-technology.com/news/newsamgens-multiple-myeloma-drug-shows-positive-outcome-in-phase-iii-trial-5870814 http://www.drugdevelopment-technology.com/news/newsamgens-multiple-myeloma-drug-shows-positive-outcome-in-phase-iii-trial-5870814 Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma. Thu, 13 Jul 2017 23:00:00 GMT Abivax reports positive data from ABX464 study for HIV-related inflammation http://www.drugdevelopment-technology.com/news/newsabivax-reports-positive-data-from-abx464-study-for-hiv-related-inflammation-5870795 http://www.drugdevelopment-technology.com/news/newsabivax-reports-positive-data-from-abx464-study-for-hiv-related-inflammation-5870795 French biotechnology firm Abivax has reported positive findings from the evaluation of the ability of its product candidate ABX464 to mitigate intestinal inflammation in HIV patients. Thu, 13 Jul 2017 23:00:00 GMT Valerion starts VAL-1221 dosing in Phase I/II trial for Pompe disease http://www.drugdevelopment-technology.com/news/newsvalerion-starts-val-1221-dosing-in-phase-iii-trial-for-pompe-disease-5869600 http://www.drugdevelopment-technology.com/news/newsvalerion-starts-val-1221-dosing-in-phase-iii-trial-for-pompe-disease-5869600 Valerion Therapeutics has started dosing patients in a Phase I/II clinical trial of VAL-1221 to treat patients suffering from late-onset Pompe disease. Wed, 12 Jul 2017 23:00:00 GMT Vifor Pharma studies Ferinject in three trials for heart failure and iron deficiency http://www.drugdevelopment-technology.com/news/newsvifor-pharma-studies-ferinject-in-three-trials-for-heart-failure-and-iron-deficiency-5870031 http://www.drugdevelopment-technology.com/news/newsvifor-pharma-studies-ferinject-in-three-trials-for-heart-failure-and-iron-deficiency-5870031 Swiss-based Vifor Pharma has initiated three clinical trials known as AFFIRM-AHF, FAIR-HF2 and HEART-FID, to assess the efficacy of Ferinject on morbidity and mortality outcomes in systolic heart failure and iron deficiency patients. Wed, 12 Jul 2017 23:00:00 GMT